• Ziprasidone Inhibits GOT1, Disrupting Glutamine Metabolism i

  2026-05-09

  The referenced study identifies ziprasidone as a novel non-competitive inhibitor of GOT1, reprogramming glutamine metabolism and redox homeostasis in pancreatic ductal adenocarcinoma (PDAC) cells. This mechanistic insight reveals new therapeutic avenues for targeting metabolic vulnerabilities in PDAC.

• Asunaprevir (BMS-650032): Potent HCV NS3 Protease Inhibitor

  2026-05-09

  Asunaprevir (BMS-650032) is a highly potent, orally administered inhibitor of the hepatitis C virus (HCV) NS3 protease, exhibiting broad genotype coverage and nanomolar efficacy. Developed by APExBIO, it is integral to research on HCV RNA replication inhibition and antiviral strategies for hepatitis C virus infection.

• Pioglitazone (SKU B2117): Reliable Pathways for Cell Viabili

  2026-05-08

  Explore how Pioglitazone (SKU B2117) from APExBIO tackles common laboratory challenges in cell viability, proliferation, and inflammatory modulation assays. This article delivers scenario-driven guidance rooted in peer-reviewed evidence and real-world protocol optimization, enabling biomedical researchers to achieve reproducible, data-backed results with confidence.

• Canagliflozin Hemihydrate: Applied Strategies in Glucose Met

  2026-05-07

  Canagliflozin hemihydrate stands out for its precision in targeting renal glucose reabsorption, enabling advanced studies in diabetes and metabolic disorder pathways. This article delivers actionable workflows, troubleshooting guidance, and contextualizes its specificity versus mTOR pathway inhibition, optimizing research strategy and reliability.

• XAV-939: Precision Tankyrase Inhibitor for Advanced Wnt Rese

  2026-05-07

  XAV-939 (NVP-XAV939) is a benchmark tankyrase 1/2 inhibitor enabling robust and reproducible Wnt/β-catenin pathway modulation in cancer, fibrosis, and stem cell differentiation studies. Its nanomolar potency and proven utility in combinatorial screening, reprogramming, and osteogenic workflows make it a linchpin for translational research.

• PDHA1 Acetylation Suppresses Cuproptosis and Drug Response i

  2026-05-06

  This study reveals how PDHA1-mediated acetylation signaling suppresses cuproptosis, attenuating the efficacy of anti-androgen therapy in castration-resistant prostate cancer (CRPC). The mechanistic link between mitochondrial metabolism, epigenetic regulation, and copper-dependent cell death highlights new avenues for overcoming therapy resistance.

• Reliable Protein Extraction: Protease and Phosphatase Inhibi

  2026-05-06

  This article addresses prevalent laboratory challenges in protein extraction and post-translational modification preservation, offering scenario-driven guidance for using the Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O), SKU K4006. Drawing on experimental best practices and recent literature, it demonstrates how APExBIO’s formulation ensures reproducible data quality in cell viability and signaling assays.

• Calnexin-Dependent Modulation of CFTR Variant Rescue in CF

  2026-05-05

  Tedman et al. systematically dissect how the ER chaperone calnexin modulates the expression and pharmacological rescue of over 200 CFTR variants. Their deep mutational scanning reveals domain-specific requirements for calnexin in CFTR folding and corrector responsiveness, with implications for personalized cystic fibrosis therapy design.

• NSC-23766: Rac GTPase Inhibitor for Advanced Cancer Research

  2026-05-05

  NSC23766 trihydrochloride stands out as a highly selective Rac1 signaling pathway inhibitor, empowering researchers to dissect oncogenic mechanisms and induce apoptosis with precision. This article delivers actionable protocols and troubleshooting insights, translating recent high-impact discoveries into robust workflows for cancer and endothelial biology.

• FITC Goat Anti-Rabbit IgG: Precision for Early Biomarker Dis

  2026-05-04

  This thought-leadership article explores the mechanistic, experimental, and strategic dimensions of fluorescent secondary antibody technology—specifically the FITC Goat Anti-Rabbit IgG (H+L) Antibody—in the context of translational biomarker discovery for diseases such as diabetic nephropathy. Integrating the latest quantitative proteomics evidence and workflow best practices, it provides actionable guidance for researchers aiming to achieve high sensitivity, specificity, and reproducibility in immunofluorescence and related assays, while highlighting clinical translation opportunities and current maturity limits.

• Pentoxifylline Suppresses Macrophage Activation via NO Inhib

  2026-05-04

  This reference study demonstrates that pentoxifylline, a broad-spectrum phosphodiesterase inhibitor, suppresses nitric oxide production and activation of macrophages both in vitro and in vivo by elevating intracellular cAMP and downregulating iNOS. The findings clarify the mechanistic role of cAMP elevation in immune regulation and provide a quantitative basis for using pentoxifylline in inflammation research models.

• Dabigatran Etexilate: Clinical Innovation as an Oral Thrombi

  2026-05-03

  This article reviews the pivotal advances of dabigatran etexilate as highlighted in the referenced clinical review, focusing on its innovation as the first oral direct thrombin inhibitor for stroke and VTE prevention. It details the pharmacological benefits, practical limitations, and research implications, bridging experimental insights with translational applications for anticoagulant research.

• PTPN2 Modulates Psoriasis via STING–STAT3 Axis and Autophagy

  2026-05-02

  This reference study uncovers a novel mechanism in which protein tyrosine phosphatase nonreceptor type 2 (PTPN2) alleviates psoriasis by directly targeting the STING–STAT3 axis and restoring autophagy in keratinocytes. The findings highlight PTPN2 as a promising therapeutic target and provide mechanistic insights relevant to STAT3 inhibitor research.

• Applied Cell Cycle Assay Kit Workflows for Phase and Apoptos

  2026-05-02

  The Cell Cycle Assay Kit (Catalog No. K2263) from APExBIO enables precise discrimination of cell cycle phases and robust apoptosis detection, empowering translational cancer research. This article delivers advanced protocol strategies, troubleshooting solutions, and cross-study insights for researchers aiming to achieve reproducible, publication-grade results in cell cycle progression analysis.

• Reserpine (N1867): Technical Guidance for Lab Applications

  2026-05-01

  Reserpine (SKU N1867) addresses the need for a high-purity reagent in neurotransmitter depletion, antihypertensive mechanism, and neuropharmacology studies. This product is not suitable for clinical, diagnostic, or veterinary applications and should be handled strictly within research protocols.

454 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page